



SpecialtyRx.GiantEagle.com  
1-844-259-1891

## Patient Information

New Patient  Current Patient

### Patient's Name

First \_\_\_\_\_ Last \_\_\_\_\_ MI \_\_\_\_\_

Male  Female

Last 4 digits of SSN \_\_\_\_\_ Date of Birth \_\_\_\_\_

Street Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ ZIP \_\_\_\_\_

Preferred Phone \_\_\_\_\_  Landline  Mobile

Alternate Phone \_\_\_\_\_  Landline  Mobile

Preferred Method of Contact  Call  Text

Email Address \_\_\_\_\_

Patient's Primary Language  English  Other If other, please specify \_\_\_\_\_

**Parent/Guardian Name (if under 18)** \_\_\_\_\_

Home Phone \_\_\_\_\_ Cell Phone \_\_\_\_\_

Email Address \_\_\_\_\_

**Alternate Caregiver/Contact** \_\_\_\_\_

OK to speak to/leave message with alternate caregiver/contact

Home Phone \_\_\_\_\_ Cell Phone \_\_\_\_\_

Email Address \_\_\_\_\_

**PLEASE ATTACH COPY OF FRONT AND BACK OF PATIENT'S INSURANCE CARD**



## Prescriber Information

Date Prescription Needed \_\_\_\_\_

Ship to Office  Patient Pickup at Retail  Ship to Home

Office Hours to Receive Shipment of Medication \_\_\_\_\_

Office Contact and Title \_\_\_\_\_

Office Contact Phone \_\_\_\_\_

**Patient's Name**

First \_\_\_\_\_ Last \_\_\_\_\_ MI \_\_\_\_\_

Date of Birth \_\_\_\_\_

Primary ICD-10 code \_\_\_\_\_ Has the patient been on this therapy before?  Yes  No

Height \_\_\_\_\_ cm Weight \_\_\_\_\_ kg Date Recorded \_\_\_\_\_

TB Test Results and Date \_\_\_\_\_

Has Hepatitis B been ruled out?  Yes  No Date \_\_\_\_\_

If No, has treatment been initiated?  Yes  No

New Therapy Induction  Therapy Change

**Other Therapies Tried and Failed**

Corticosteroids Date \_\_\_\_\_

Methotrexate Date \_\_\_\_\_

Azathioprine/6MP Date \_\_\_\_\_

Sulfasalazine/Mesalamine Date \_\_\_\_\_

Cyclosporine Date \_\_\_\_\_

Other Biologics \_\_\_\_\_ Date \_\_\_\_\_

Other \_\_\_\_\_

Additional justification for drug \_\_\_\_\_

NKDA  Known drug allergies \_\_\_\_\_

Concurrent Medications \_\_\_\_\_

**Prescribing Information**

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> Humira (adalimumab) <b>Adult</b>	<b>Starter:</b>  <b>CITRATE FREE</b> <input type="checkbox"/> 80mg/0.8mL pen starter kit (3 Pens)	<b>Starter:</b>  Inject 160mg (contents of 2 devices) subcutaneously on day 1 followed by 80mg subcutaneously 2 weeks later on day 15. Then start maintenance dose on day 29.	<b>Starter:</b>  Qty: 1 kit  Refills: 0
	<b>Maintenance:</b>  <b>CITRATE FREE</b> <input type="checkbox"/> 40mg/0.4mL pen <input type="checkbox"/> 40mg/0.4mL prefilled syringe  <b>ORIGINAL FORMULATION</b> <input type="checkbox"/> 40mg/0.8mL pen <input type="checkbox"/> 40mg/0.8mL prefilled syringe	<b>Maintenance:</b>  <input type="checkbox"/> Inject 40mg subcutaneously every other week.  <input type="checkbox"/> Inject 40mg subcutaneously every week.	<b>Maintenance:</b>  Qty: <input type="checkbox"/> 1 kit (2 devices) <input type="checkbox"/> 2 kits (4 devices) <input type="checkbox"/> 3 kits (6 devices) <input type="checkbox"/> 6 kits (12 devices)  Refills: _____

# Prescribing Information Cont.

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> Humira (adalimumab) <b>Pediatric</b>  Patient weight _____ kg	<b>Starter:</b>  <b>CITRATE FREE</b> <input type="checkbox"/> 80mg/0.8mL prefilled syringe starter kit (3 syringes)  <input type="checkbox"/> 80mg/0.8mL and 40mg/0.4mL syringe starter kit	<b>Starter:</b> <input type="checkbox"/> Inject 160mg (contents of 2 devices) subcutaneously on day 1 followed by 80mg subcutaneously 2 weeks later on day 15. Then start maintenance dose on day 29.  <input type="checkbox"/> Inject 80mg subcutaneously on day 1 followed by 40mg subcutaneously 2 weeks later on day 15. Then start maintenance dose on day 29.	<b>Starter:</b> Qty: 1 kit  Refills: 0
	<b>Maintenance:</b> <b>CITRATE FREE</b> <input type="checkbox"/> 40mg/0.4mL pen <input type="checkbox"/> 40mg/0.4mL prefilled syringe <input type="checkbox"/> 20mg/0.2mL prefilled syringe  <b>ORIGINAL FORMULATION</b> <input type="checkbox"/> 40mg/0.8mL pen <input type="checkbox"/> 40mg/0.8mL prefilled syringe	<b>Maintenance:</b> <input type="checkbox"/> Inject 20mg subcutaneously every other week <input type="checkbox"/> Inject 40mg subcutaneously every other week <input type="checkbox"/> Inject 20mg subcutaneously weekly <input type="checkbox"/> Inject 40mg subcutaneously weekly	<b>Maintenance:</b> Qty: <input type="checkbox"/> 1 kit (2 devices) <input type="checkbox"/> 2 kits (4 devices) <input type="checkbox"/> 3 kits (6 devices) <input type="checkbox"/> 6 kits (12 devices) <input type="checkbox"/> Other _____ Refills: _____
<input type="checkbox"/> Simponi (golimumab)	<input type="checkbox"/> 100mg/mL prefilled syringe  <input type="checkbox"/> 100mg/mL SmartJect auto-injector	<b>Starter:</b> <input type="checkbox"/> Inject 200mg subcutaneously at week 0, followed by 100mg subcutaneously at week 2. Then start maintenance dose at week 6.	<b>Starter:</b> Qty: 3 devices  Refills: 0
		<b>Maintenance:</b> <input type="checkbox"/> Inject 100mg subcutaneously every 4 weeks	<b>Maintenance:</b> Qty: <input type="checkbox"/> 1 device <input type="checkbox"/> 3 devices  Refills: _____
<input type="checkbox"/> Stelara (ustekinumab)  Patient weight _____ kg	<b>Starter:</b> <input type="checkbox"/> ≤55kg = 260mg vial <input type="checkbox"/> >55kg to 85kg = 390mg vial <input type="checkbox"/> >85kg = 520mg vial	<b>Starter:</b> <input type="checkbox"/> Infuse 260mg over at least 1 hour intravenously as a single dose. Begin maintenance dose 8 weeks after the IV induction. <input type="checkbox"/> Infuse 390mg over at least 1 hour intravenously as a single dose. Begin maintenance dose 8 weeks after the IV induction. <input type="checkbox"/> Infuse 520mg over at least 1 hour intravenously as a single dose. Begin maintenance dose 8 weeks after the IV induction.	<b>Starter:</b> Qty: <input type="checkbox"/> 2 vials (260mg) <input type="checkbox"/> 3 vials (390mg) <input type="checkbox"/> 4 vials (520mg)  Refills: 0
		<b>Maintenance:</b> <input type="checkbox"/> 90mg/ml prefilled syringe	<b>Maintenance:</b> <input type="checkbox"/> Inject 90mg/mL subcutaneously every 8 weeks
<input type="checkbox"/> Cimzia (certolizumab pegol)	<b>Starter:</b> <input type="checkbox"/> 200mg/mL prefilled syringes (1 kit = 6 syringes, 3 doses)	<b>Starter:</b> <input type="checkbox"/> Inject the contents of 2 syringes (400mg) subcutaneously at weeks 0, 2, and 4	<b>Starter:</b> <input type="checkbox"/> 1 kit  Refills: 0
	<b>Maintenance:</b> <input type="checkbox"/> 200mg/mL prefilled syringes (total dose = 400mg)	<b>Maintenance:</b> <input type="checkbox"/> Inject the contents of 2 syringes (400mg) subcutaneously every 4 weeks	<b>Maintenance:</b> <input type="checkbox"/> 2 syringes <input type="checkbox"/> 6 syringes  Refills: _____

# Prescribing Information Cont.

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> Remicade (infliximab) OR biosimilar <input type="checkbox"/> Avsola (infliximab-axxa) <input type="checkbox"/> Inflectra (infliximab-dyyb) <input type="checkbox"/> Renflexis (infliximab-abda) Patient weight _____ kg	100mg vial	<b>Starter:</b> <input type="checkbox"/> Infuse _____mg (5mg/kg) intravenously at week 0, 2, and 6, then every 8 weeks thereafter  <b>Maintenance:</b> <input type="checkbox"/> Infuse _____mg (5mg/kg) intravenously every 8 weeks <input type="checkbox"/> Infuse _____mg (10mg/kg) intravenously every 8 weeks	<b>Starter:</b> Qty: _____vial(s) Refills: 0  <b>Maintenance:</b> Qty: _____vial(s) Refills: _____
<input type="checkbox"/> Entyvio (vedolizumab)	300mg vial	<b>Starter:</b> <input type="checkbox"/> Infuse 300mg intravenously at weeks 0, 2, and 6, then every 8 weeks thereafter  <b>Maintenance:</b> <input type="checkbox"/> Infuse 300mg intravenously every 8 weeks	<b>Starter:</b> Qty: _____vial(s) Refills: 0  <b>Maintenance:</b> Qty: _____vial(s) Refills: _____
<input type="checkbox"/> Rinvoq (upadacitinib)	<b>Starter:</b> <input type="checkbox"/> 45mg tablet	<b>Starter:</b> <input type="checkbox"/> Take 45mg by mouth once daily for 8 weeks	<b>Starter:</b> <input type="checkbox"/> 28 tablets <input type="checkbox"/> 56 tablets Refills: 0
	<b>Maintenance:</b> <input type="checkbox"/> 15mg tablet <input type="checkbox"/> 30mg tablet	<b>Maintenance:</b> <input type="checkbox"/> Take 15mg by mouth once daily <input type="checkbox"/> Take 30mg by mouth once daily	<b>Maintenance:</b> <input type="checkbox"/> 30 tablets <input type="checkbox"/> 90 tablets Refills: _____
<input type="checkbox"/> Skyrizi (risankizumab-rzaa)	<b>Starter:</b> <input type="checkbox"/> 600mg/10mL vial	<b>Starter:</b> <input type="checkbox"/> Infuse 600mg intravenously at weeks 0,4,and 8, then start maintenance at week 12.	<b>Starter:</b> Qty: <input type="checkbox"/> 1 vial <input type="checkbox"/> _____vial(s) Refills: _____
	<b>Maintenance:</b> <input type="checkbox"/> 360mg/2.4mL solution cartridge <input type="checkbox"/> 180mg/1.2ml solution cartridge	<b>Maintenance:</b> <input type="checkbox"/> Inject _____mg subcutaneously at week 12 and every 8 weeks thereafter <input type="checkbox"/> Inject _____mg subcutaneously every 8 weeks	<b>Maintenance:</b> Qty: <input type="checkbox"/> 1 cartridge Refills: _____
<input type="checkbox"/> Xeljanz (tofacitinib citrate)	<input type="checkbox"/> 10mg tablet <input type="checkbox"/> 5mg tablet	<input type="checkbox"/> Take 10mg by mouth twice daily <input type="checkbox"/> Take 5mg by mouth twice daily	Qty: _____ Refills: _____
<input type="checkbox"/> Xeljanz XR (tofacitinib citrate extended release)	<input type="checkbox"/> 22mg XR tablet <input type="checkbox"/> 11mg XR tablet	<input type="checkbox"/> Take 22mg by mouth once daily <input type="checkbox"/> Take 11mg by mouth once daily	Qty: _____ Refills: _____
<input type="checkbox"/> Zeposia (ozanimod HCl)	<b>Starter:</b> <input type="checkbox"/> 4 x 0.23mg capsules and 3x 0.46mg capsules <b>(7 day starter kit)</b> <input type="checkbox"/> 4 x 0.23mg capsules, 3x 0.46mg capsules and 30x 0.92mg capsules <b>(37 day starter kit)</b>	<b>Starter:</b> Take 0.23mg by mouth once daily on days 1 through 4, take 0.46mg on days 5 through 7, and then take 0.92mg once daily starting on day 8	<b>Starter:</b> Qty: <input type="checkbox"/> 1 starter kit (7 days) <input type="checkbox"/> 1 starter kit (37 days) Refills: 0
	<b>Maintenance:</b> <input type="checkbox"/> 0.92mg capsules	<b>Maintenance:</b> <input type="checkbox"/> Take 0.92mg by mouth once daily	Qty: _____ capsules Refills: _____

Prescriber Name \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_

Email Address \_\_\_\_\_

Office Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ ZIP \_\_\_\_\_

State License \_\_\_\_\_ DEA \_\_\_\_\_ NPI \_\_\_\_\_

In order for brand name to be dispensed, prescriber must hand write "Brand Medically Necessary" or "Brand Necessary" in the space below:

\_\_\_\_\_

I authorize this prescription and for Giant Eagle Specialty Pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization process.

Prescriber signature required. NO STAMPS. Prescriber attests this is his/her legal signature.

Prescriber signature \_\_\_\_\_ Date \_\_\_\_\_